Opus Genetics Inc. (IRD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for IRD, including 5 press releases and news items, 4 insider trades and 3 SEC filings. The most recent was published Nov 3, 2026.
IRD rankings
Financial highlights
Full financials- Revenue, TTM
- $9.86M
- Revenue growth
- -36.1%
- Net income, TTM
- -$107.61M
- Net margin
- -1091.8%
- Cash
- $88.81M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks61+1200%
2026-05-102026-11-01
Mix2990d
- Other8(28%)
- Insider8(28%)
- SEC Filings7(24%)
- Leadership2(7%)
- Earnings2(7%)
- Offering2(7%)
Latest news
25 items- PROpus Genetics to Present at the Guggenheim Annual Healthcare Innovation ConferenceRESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in a Fireside Chat at the Guggenheim Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 11:00 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to
- PROpus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted in the form of options t
- PROpus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive OperationsRESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the appointments of Andrew Murphy, Ph.D., as Chief Scientific Officer and Jamie Lynne Hart, M.S., M.P.H., as Executive Director, Executive Operations. These appointments strengthen Opus Genetics’ scientific and operational capabilities as the Company advances its pipeline of gene therapies for inherited retinal diseases. "As we continue to advance our clinical programs and expand our
- INSIDERChief Operating Officer Schachle Joseph K sold $16,994 worth of shares (4,767 units at $3.57) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERPresident Yerxa Benjamin R sold $117,365 worth of shares (33,189 units at $3.54) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Financial Officer Gagnon Robert E. sold $49,650 worth of shares (14,000 units at $3.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Executive Officer Magrath George sold $34,384 worth of shares (9,591 units at $3.59) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form 8-K filed by Opus Genetics Inc.8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaFDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by positive results from pivotal Phase 3 VEGA-2 and VEGA-3 trials, which met primary and all key secondary efficacy endpoints RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has approved the Com
- SECSEC Form 8-K filed by Opus Genetics Inc.8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses link retinal structure to visual function, enabling focus on regions most likely to respond to treatment OPGx-LCA5 demonstrated sustained improvements in visual acuity and light sensitivity through 24 months in adults, with encouraging results in pediatric participants through six months in the Company’s Phase 1/2/3 clinical trial Phase 3 clinical trial dosing for OPGx-LCA5 expected in the fourth quarter of 2026 RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIR
- PROpus Genetics to Present at the Chardan Annual Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the Chardan Annual Healthcare Conference on Tuesday, October 20, 2026 at 10:00 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness
- INSIDERDirector Foundation Fighting Blindness Retinal Degeneration Fund sold $2,755,981 worth of shares (556,000 units at $4.96) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Executive Officer Magrath George exercised 392,157 shares at a strike of $1.15 and covered exercise/tax liability with 75,541 shares, increasing direct ownership by 18% to 2,048,485 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PRBig Pharma Setbacks Create a New Wave of Rebound PlaysDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE:NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when posit
- PRFour Biotech Stories Heating Up Right NowDENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity. NeOnc Raises $15
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed in four participants FDA aligned on ≥3 decibels microperimetry improvement in conjunction with patient reported outcomes as a potential pivotal endpoint Clinically meaningful best-corrected visual acuity improvements in 3 of 5 participants and retinal sensitivity improvements on microperimetry observed in 3 of 4 evaluable participants Cohort 2 over-enrolled, with dosing expected to be completed in Q4 2026 and topline 3
- INSIDERChief Financial Officer Gagnon Robert E. sold $127,212 worth of shares (28,000 units at $4.54) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 556,375 units (SEC Form 4) to cover withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERDirector Gallagher Cam exercised 784,314 shares at a strike of $1.15, increasing direct ownership by 39% to 2,800,111 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- PROpus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology ConferencesTopline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ("Opus" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor c
- PRLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the
- PROpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to three non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted in the form of options
IRD FAQ
9 questionsWhat is the latest news on IRD?
In the last 30 days Quantisnow tracked 13 wire items for IRD: 5 press releases and news items, 4 insider trades, 3 SEC filings and 1 leadership change. The most recent was published on November 3, 2026.What is IRD revenue?
Opus Genetics Inc. (IRD) reported $9.86M of revenue for the twelve months ended Jun 30, 2026. That is down 36.1% from the year before. Revenue for fiscal 2025 was $14.20M.Is IRD profitable?
No. Opus Genetics Inc. reported a net loss of $107.61M for the twelve months ended Jun 30, 2026.How much cash and debt does IRD have?
Opus Genetics Inc. reported $88.81M in cash and cash equivalents and $35.28M of debt on its most recent balance sheet in SEC filings.Where does IRD stock trade?
Opus Genetics Inc. (IRD) is listed on NASDAQ.What sector and industry is IRD in?
Opus Genetics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRD?
Opus Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-07-29. Recent price targets range from $7.00 to $16.00.What companies are similar to IRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRD side-by-side with any of them on Quantisnow.How can I track IRD on Quantisnow?
Quantisnow aggregates Opus Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRD to receive live email and push alerts on every new disclosure.